

# Index

## A

- AADvac1, 75
- ABBV-8E12, 76
- Abeotaxane (TPI-287), 73
- ABvac40, 29
- Acetylcholine, 11, 156, 170, 171, 182, 192, 194
- Acetylcholinesterase (AChE)
- AD treatment, use in, 170
  - amyloid plaques, production of, 171, 176
  - amyloid-beta accumulation, relationship between, 11
  - binding pocket, 174
  - catalytic site of, 174, 176
  - enzymes, 183
  - inhibitors, 71, 156, 171, 172, 173, 174, 175–176, 177, 185–187, 189, 192, 196–197, 198, 208
  - NFTs, role in producing, 171
  - retaining, 172
- ACI-24, 29, 31
- ACI-35, 75
- Aducanumab (BIIB037), 24, 39–40, 157
- Affitope AD02, 31
- Aging, as risk factor for AD, 137
- Akt, 103, 104, 105, 106, 112
- Aluminum (Al), 31, 84, 86
- Alzheimer Association, 100
- Alzheimer, Alois, 2
- Alzheimer's disease
- blood-brain barrier, role of (*see* blood-brain barrier)
  - characteristics of, 2, 151
  - decline, 6, 108
  - diabetes, relationship between (*see* diabetes)
  - environmental factors, 152
  - epigenetic modifications in (*see* epigenetics in AD)
  - etiology (*see* etiology of Alzheimer's)
  - genetics, role of (*see* genetics, Alzheimer's)
  - inflammation, role in Alzheimer's (*see* inflammation, role in Alzheimer's)
  - manifestations of, 2, 3
  - neurodegeneration, 8, 52, 71, 73, 75, 77, 90, 120, 169
  - neuroinflammatory changes, 70, 92
  - neuropsychiatric manifestations, 166–167
  - nondiabetic, 102, 103, 104, 106, 112 (*see also* diabetes)
  - overview, 70, 135, 136, 165, 166, 181
  - pathogenesis (*see* pathogenesis, Alzheimer's disease)
  - pathogenic mechanisms, 62
  - pathology, 166, 167
  - preclinical, 29, 71, 120, 159, 198
  - preclinical drug candidate, 34, 192
  - prevalence (*see* prevalence, Alzheimer's disease)
  - progression, 160
  - risk factors, 2
  - stages, 2, 6, 77, 155
  - synaptic losses, 168

- AMPK, 109
- Amyloid cascade hypothesis, 11, 24, 51, 52, 167–168, 181, 185
- Amyloid precursor protein (APP), 83, 85–86, 90, 108, 120, 167–168
- Amyloid  $\beta$ 40 (A $\beta$ 40), 29, 36–37, 52, 54, 57–58, 152, 168, 215
- Amyloid  $\beta$ 42 (A $\beta$ 42), 58, 60–61, 89, 108, 111, 112, 152, 167–168
- Amyloid- $\beta$ , 85, 119. *See also* amyloid- $\beta$  plaques
- amyloid hypothesis (*see* amyloid cascade hypothesis)
  - antiaggregation effects, 187–188
  - antimicrobial properties, 156
  - inhibitors, 188–189
  - metal-binding properties, 87
  - peptides, 25, 108, 112, 156, 181
- Amyloid- $\beta$  plaques, 1, 5
- aggregation in brain, 52, 87, 166
  - amyloid hypothesis (*see* amyloid cascade hypothesis)
  - binding affinity, 37
  - brain, accumulation in, 24, 51–52, 153
  - diffuse, 166
  - immunotherapy, 77
  - increases of, in diabetics, 100
  - metals, relationship between, 86
  - reducing, 38, 40, 52
  - role of, in AD, 41, 140, 151, 152
  - tau proteins, combination therapy directed to, 79
  - vasculature surrounding, 143
- AN1792 vaccine, 28, 29
- APKC, 99, 103, 104, 105, 106, 107, 110, 112. *See also* hepatic aPKC
- activators, 100, 111
  - brain activity, 101
  - inhibitors, 108–110
  - memory function, relationship between, 110–111
  - recombinant, 108
- Apolipoprotein E gene  $\epsilon$ 4 allele (APOE  $\epsilon$ 4), 120, 140, 145, 157
- Apolipoproteins E (ApoEs), 70, 140, 153, 154
- AstraZeneca, 41
- Astrocyte cell culture model, 118
- Astrocytes, 4, 120, 123, 125, 127, 138, 141, 153, 168, 169, 211
- ATP-binding cassette (ABC) transporters, 118
- Atypical protein kinase C, 99, 100–101
- Aurothiomalate [ATM], 105, 106
- Autophagy lysosome pathway, 11
- AZP2006, 72
- A $\beta$  plaques. *See* amyloid- $\beta$  plaques
- A $\beta$  precursor protein (APP), 3, 24, 25
- ## B
- BACE1 mRNA, 108
- Bacopa, 205, 209, 211–213
- BAN2401, 38–39, 157
- Bapineuzumab, 34
- BAPTA, 89
- Benzyl piperidone, 173–174
- Berberine, 205, 206, 215
- Beta-site amyloid precursor protein cleaving enzyme 1 (BACE1), 100, 103, 106, 107, 108
- AD, role in pathogenesis of, 101–102
- inhibitors, 158, 185–186, 187
- interactions with, 191
- levels, 101
- processing APPs, role in, 185
- regulating, 160
- Bioavailability of drugs, 128

Biogen, 40

Blood-brain barrier, 73, 84, 89, 106

- AD-related changes, 120–121
- brain endothelial cells (BECs) (*see* brain endothelial cells (BECs))
- cognitive impairment, as marker of, 140
- damage, 145
- defining, 117
- description, 136
- deterioration, 137
- disruption, 137
- drug delivery across, 118, 127–128, 128–129
- dysfunction, in AD, 127, 128, 129
- focused ultrasound use, 128
- human versus rodent, 122
- immune responses, 118
- integrity of, 118, 125, 136
- leakage, 120, 140
- models, 2D, 125
- models, 3D, 126–127
- neuroimmunity, 138
- organoids, 127
- overview, 117, 118–120
- penetrating, 187
- permeability, 122, 135, 139, 194, 197
- preclinical models, 125
- SPARC effect on, 141, 142–143
- in vitro model development, 117, 123, 125, 126, 129

Brain endothelial cells (BECs), 118

- degeneration, 120
- iBECs, 124
- immortalized, 123, 124
- primary, 123, 124

Brain's default mode network (BDMN), 153

Breast cancer resistance protein (BCRP), 118

Butyrylcholinesterase (BuChE), 184

## C

C-terminal fragments (CTFs), 55, 57

Cadmium (Cd), 84, 86–87

Calcium (Ca), 87

Calcium channel blockers (CCBs), 176–177

Cannabinoid receptors, 195

Canosine, 59

Capsaicin, 205, 214–215

Carrier mediated transport (CMT), 118

Cascade hypothesis, 24

Ceramide, 104

Cerebellum, 168

Chelators, metal, 52, 59, 86, 89, 90, 91, 170

Chimeric conjugates, 165, 172, 175–176

Cholinergic hypothesis, 11, 52, 169

Cholinergic neurotransmission, 192–194

Cholinesterase inhibitors, 24, 155, 165, 170, 182, 189

Cholinoesterases, 196

Clinical trials, ethical standards for, 78

Clinioquinol (CQ), 89

Cobalt (Co), 87, 90

Conventional PKCs (cPKCs), 107–108

Convolutional neural network (CNN) algorithm, 145

Copper (Cu), 84, 86, 87, 88, 89, 170

Copper-bis(thiosemicarbazono), 90

Crenzumab, 35

CRISPR, 128

Curcumin, 205, 206, 213–214

Cysteine, 86

## D

DAG-activated cPKCs, 107–108

Davunetide peptide, 81

Dementia. *See also* Alzheimer's disease

- Dementia forms, 1
- Diabetes
- copper overload, 89
  - hyperinsulinemia, 99–100, 101, 104–105, 106, 112
  - insulin receptors (IR), 102, 103, 104, 112
  - insulin-resistant, 99, 101, 102, 106
  - insulin-resistant Alzheimer's disease, 100
  - liver, insulin action in, 103
  - metabolic syndrome (MetS) (*see* metabolic syndrome (MetS))
  - obesity/type-2-diabetic (O/T2D) states, 99, 102, 103, 105, 109, 111, 112 (*see also* obesity)
  - pre-diabetes, 102, 103
  - type 2, 100, 102, 103
- Diagnosis, Alzheimer's disease, 53
- Disability Assessment for Dementia (DAD), 34
- DNA methyltransferases, 151, 154
- DNA-demethylating agents, 158
- Dominantly Inherited Alzheimer Network (DIAN) trial, 38
- Donecopride, 192
- Donepezil, 170, 171, 172–174, 182, 185, 187, 195, 196
- Down Syndrome, 4, 31, 213
- DP-109, 89
- Drug delivery systems (DDSs), 91
- Drug reactions, adverse, 206
- Dystrophic neurites, 152
- E**
- Early-onset Alzheimer's disease (EOAD), 3, 24
- Endothelial cells, brain. *See* brain endothelial cells (BECs)
- Enzyme inhibitors, 196
- Epigenetics in AD
- anti-amyloid- $\beta$  therapies, 157
  - brain evolution, role in, 155
  - changes in, 151, 156, 160
  - changes, reversing, 156
  - gene modulation, 154, 158
  - therapies, 156–161
- Epothilone D, 73
- Etiology of Alzheimer's, 2, 3–5. *See also* genetics, Alzheimer's
- Excitotoxicity, 92
- F**
- Flavinoids, 214
- Flubiprofen, 197
- Fluorination, 53
- Focused ultrasound (FUCs), 128
- Free radicals, 170
- Fyn tyrosine kinase, 72
- G**
- G protein-coupled receptors (GPCRs), 184, 192, 194, 198
- Galantamine, 155, 170, 182
- Gantenerumab, 31–32, 36, 38
- Genentech, 35
- Genetics, Alzheimer's
- environmental factors, interaction between, 152
  - factor in AD cases, 2
  - gene mutations, 24–25
  - inherited forms, 1, 3, 70
  - Mendelian inheritance, 3
  - mutations, 3
  - risk factors, 3–4
- Ginkgo biloba, 205, 206–207, 207–208

Glucose transport, 137  
 Glycogen synthase kinase-3 (GSK-3), 72  
 GSK-3 $\beta$ , 86, 189, 190, 191

## H

HDAC inhibitors (HDACis), 158–159  
 Hepatic aPKC, 106. *See also* aPKC  
 Hevin, 136, 141, 143  
 Hippocampus, 152, 158, 160, 167  
 Histone acetylation, 151, 157–158  
 Histone acetyltransferases (HATs),  
     155, 160  
 Histone deacetylases (HDACs), 155  
 Histone H4 with acetylation at the 16th  
     lysine residue protein (H4K16ac),  
     157–158  
 Homeostasis, brain, 136  
 Homeostasis, metal. *See* metal homeostasis  
 Huntington's chorea, 213  
 Hyper-phosphorylated tau, 129  
 Hyperinsulinization, of brain, 106  
 Hyperosmosis, 127  
 Hyperphosphorylation of tau proteins.  
     *See* Tau proteins

## I

IBECs, 124, 127  
 ICAP, 109, 110  
 ICAPP, 109  
 IL-1 $\beta$ , 108, 111, 187  
 Immunotherapy strategies

    ABvac40, 29–30  
     ACI-24, 29, 31  
     active-A $\beta$ -directed strategies, 28–29  
     Affitope AD02, 31  
     anti-A $\beta$  strategies, 24, 25–28  
     antibodies, clinical trials, 24

    BAN2401, 38–39  
     bapineuzumab, 34  
     crenuzumab, 35  
     gantenerumab, 36, 38  
     MEDI1814, 40–41  
     monoclonal antibodies, passive  
         immunotherapy with, 31–32  
     ponezumab, 36–37  
     SAR228810, 41  
     solanezumab, 37–38  
     UB 311, 31  
     vaccines (*see* vaccines, for AD)  
 Induced pluripotent stem cell, 118,  
     124–125  
 Inflammation, role in Alzheimer's, 4, 10,  
     75, 104  
 Inherited forms of Alzheimer's. *See*  
     genetics, Alzheimer's  
 Insulin resistance, brain, 102  
 Insulin, role in AD, 9, 10  
 Interlaminar astrocytes, 123  
 Intravenous immunoglobulin (IVIg),  
     75, 76  
 Ionophores  
 IPSCs, 124, 128  
 Iron (Fe), 84, 86, 87, 90, 170

## K

Kaempferol, 205, 214  
 Keyhole limpet cyanine (KHL) carrier  
     proteins, 29

## L

L-peptides, 57  
 Late-onset Alzheimer's disease (LOAD), 3  
 Lead (Pb), 84  
 Limbic system, 152

**M**

Machine learning (ML) algorithms, 144  
Magnesium (Mg), 87  
Mammalian target of rapamycin  
(mTOR), 104  
Manganese (Mn), 84, 86, 87  
Mannitol, 127  
MAOs (MAO-A and MAO-B), 196  
MAP kinases, 86  
MEDI1814, 40–41  
Memantine, 156, 170, 172, 182  
Mendelian inheritance, 3  
Met 35, 53–54  
Metabolic syndrome (MetS), 100, 103,  
105, 106, 111. *See also* diabetes  
Metal chelators. *See* chelators, metal  
Metal homeostasis, 83, 87–88  
Metal hypothesis, 191  
Metal imbalance hypothesis, 182  
Metal ion hypothesis, 170  
Metal protein attenuating compounds  
(MPACs), 88–89, 90  
Metal-binding proteins, 84  
Metal-focused interventions. *See*  
trace metals  
Metallochaperones, 84, 87–88, 90  
Metals, trace. *See* trace metals; specific  
metals  
Meynert, 152  
Microglia, 138, 141, 187  
MicroRNA expression, 151  
Microtubule-associated protein tau  
(MAPT), 5, 154  
Mild traumatic brain injury (mTBI),  
139–140  
MiRNA, 160  
Molybdenum (Mo), 87  
Monoclonal antibodies, 31–32

MRNA, 111  
Multidrug resistance-associated proteins  
(MRPs), 118  
Multitarget-directed ligands (MTDLs).  
*See* multitargeted ligands (MTLs)  
Multitargeted ligands (MTLs), 182,  
183–185  
cholinergic inhibition, 194–195  
cholinergic neurotransmission,  
192–194  
cholinesterases, targeting, 195  
endocannabinoid system, targeting, 195  
H3R antagonism, 194–195  
serotonic, influence on, 192

**N**

N-benzylpiperidine, 185–186, 187, 193,  
196  
N-methyl-D-aspartate (NMDA) antagonists  
(glutamate inhibitor), 170,  
171–172  
N-methyl-D-aspartate (NMDA)  
neurotransmissions, 184  
N-methyl-D-aspartate (NMDA) receptor  
antagonists, 71, 182  
N-methyl-D-aspartate receptor  
agonist, 24  
N-methylation, 53  
Namzaric, 182  
Nanomedicine, 83  
Natural substances, use in AD. *See also*  
specific substances  
drug interactions, 205  
overview, 205  
Paquid study, 208–209  
Neocortex, 6  
Neurocognitive disorders, definition,  
206, 215

Neurodegeneration in Alzheimer's, 1,  
169, 170

Neurofibrillary tau tangles (NFTs), 1, 2,  
5–6, 86, 92, 140, 151, 152, 166,  
167, 169  
formation, 8

Neuroimmunity, 138

Neuroinflammation, 138–139

Neuropathology of Alzheimer's  
autophagy lysosome pathway, 11  
 $A\beta$  plaques (*see amyloid- $\beta$  plaques*)  
cholinergic hypothesis, 11  
hypoglycemia, 10  
inflammation, role in Alzheimer's  
(*see inflammation, role in*  
*Alzheimer's*)  
insulin, 9, 10  
mitochondrial dysfunction, 9  
neurofibrillary tau tangles (NFTs)  
(*see neurofibrillary tau tangles*  
*(NFTs)*)  
overview, 5  
oxidative stress, 9  
ubiquitin-proteasome system (UPS),  
10–11  
vascular dysfunction, 10

Neuroplasticity, 153

Neurovascular unit (NVU), 118

NF $\kappa$ B, 108, 111–112

NMDA receptors, 7

NOR tests, 111

Novartis, 29

Nutritional interventions, AD, 87

NVU, 124

## O

Obesity, 102, 103, 104, 106. *See also*  
diabetes

Oligodendrocytes, 168

Oligomers, 7

Oxidative stress, 87, 104, 153,  
169–170, 182

## P

P-glycoprotein (P-gp), 118

Paired helical fragments (PHFs), 6

PAMPA, 196

Parkinson's disease, 213

Pathogenesis, Alzheimer's disease  
APP, 7–8  
 $A\beta$ , 7–8  
complexity, 196  
hallmarks of, 182  
NFTs, 8–9  
overview, 7  
pathogenic mechanisms, 62  
tau, 8–9

Penicillamine, 90

Peptides  
Alzheimer's disease, use as strategy  
for, 52  
inhibitors (*see peptidic inhibitors*)  
library screening, 59–61

Peptidic inhibitors  
 $A\beta$  peptide inhibitors, 54, 57–58,  
61–62  
non- $A\beta$ -based peptide inhibitors, 59  
overview, 53–54

Pericytes, 118, 120–121, 125, 127

Peripheral endothelial cells, 118

Phage display, 59

Phagocytes, 25

Phosphatidic acid (PA), 104

PKC- $\delta$ , 108

PKC- $\lambda$ , 108, 109, 111

PKM $\zeta$ , 109, 110, 111

Polymeric nanoparticles, 91  
 Polypharmacology in AD. *See also*  
     specific drugs  
     drugs used, 182  
     multifunctional agents, 185–188  
     multitargeted ligands (MTLs) (*see*  
       multitargeted ligands (MTLs))  
 Ponezumab, 36–37  
 Post-mortem histopathology of  
     Alzheimer's, 6  
 Potassium (K), 87  
 Pre-diabetes. *See* diabetes  
 Presenilin 1 (PSEN1), 3, 24, 120, 168  
 Presenilin 2 (PSEN2), 3, 24, 168  
 Prevalence, Alzheimer's disease, 2, 24, 52,  
     70, 100, 166  
 Proline (Pro), 86  
 Protein-fragment complementation assay  
     (PCA), 81  
 Pyrrolidine dithiocarbamate (PDTC), 90

## Q

Quercetin, 205, 206, 214

## R

RAWM tests, 111  
 Reactive oxygen species (ROS), 206  
 Receptor-mediated transcytosis  
     (RMT), 118  
 Reelin, 154–155  
 Repressor element 1-silencing  
     transcription factor (REST), 157  
 Resveratrol, 205, 206, 213  
 Retro-inverso cyclization, 53  
 Rivastigmine, 170, 171, 172,  
     174–175, 182  
 Rottlerin, 107

## S

Sanofi, 41  
 SAR228810, 41  
 Saracatinib, 72  
 Secreted protein acidic and rich in cysteine  
     (SPARC) protein, 135–136,  
     140–141, 142–143, 144, 145  
 Serine (Ser), 86  
 Serotonin, 192–193  
 SHANK proteins, 92  
 Shogaol–huprine hybrids, 189  
 Short-term memory decline, 1  
 Sodium (Na), 87  
 Solanezumab, 37–38  
 SPARC. *See* secreted protein acidic and  
     rich in cysteine (SPARC) protein  
 Sulforaphane, 159  
 Synaptophysin, 89

## T

T-cells, 25–26  
 Tacrine, 170, 171, 172, 175–176, 191,  
     193, 198  
 Tau hypothesis, 168–169, 182  
 Tau proteins  
     aggregation prevention, 73–74,  
     188, 189  
     Alzheimer's disease, as factor in, 71  
     amyloid, combination therapy directed  
     to, 79  
     antibodies, 76, 77  
     hyperphosphorylation, 86, 90  
     immunotherapy, 74–76, 77  
     impact of incorrect levels of, 8–9  
     inhibitors, 188–189  
     isoforms of, 8  
     metal-binding properties, 87



- neuropathophysiological functions, 77  
p-Tau, 34, 106  
PET imaging of, 74  
phosphorylation, 72  
protein hypothesis, 52  
protein therapy, 69  
role of, 8  
T-Tau, 34  
trace metals, relationship between,  
    83, 85  
    zinc, interactions with, 86  
TEER, 124, 125  
Tetrahydroisoquinoline–benzimidazole  
    derivatives, 187  
Threonine (Thr), 86  
Tideglusib, 72  
TJ proteins (TJPs), 122, 124  
TNF- $\alpha$ , 108, 111–112, 187  
Trace metals. *See also* specific metals  
    Alzheimer's disease, relationship  
        between, 84, 85, 91  
    deficiencies, 87  
    dysregulation of, 84  
    homeostasis (*see* metal homeostasis)  
    imbalance of, hypothesis (*see* metal  
        hypothesis)  
    metal-focused interventions, 88–89  
    supplementation, 87  
    tau proteins, relationship between, 84  
Transcriptional neoteny, 153  
Transwell models, 125, 126  
Traumatic brain injury (TBI), 139–140  
Triethylenetetramine (TETA), 89, 90  
Tryptophan hydroxylase, 84  
Tyrosine hydroxylase, 84
- U**
- UB 311, 31  
Ubiquitin-proteasome system (UPS),  
    10–11
- V**
- Vaccines, for AD, 23, 69, 74, 75. *See also*  
    specific vaccines  
Vascular dementia, 4  
Virtual screening, 136  
Vitamin B3, 159
- Z**
- Zinc (Zn), 84, 86, 87, 88, 89, 90, 91, 92

Doi: <https://doi.org/10.36255/exonpublications.alzheimersdisease.2020.ind>

